参考文献/References:
[1] Chorin E,Rozenbaum Z,Topilsky Y,et al. Tricuspid regurgitation and long-term clinical outcomes[J]. Eur Heart J Cardiovasc Imaging,2020,21(2):157-165.
[2] Offen S,Playford D,Strange G,et al. Adverse prognostic impact of even mild or moderate tricuspid regurgitation:insights from the national echocardiography database of australia[J]. J Am Soc Echocardiogr,2022,35(8):810-817.
[3] Kilic A,Saha-Chaudhuri P,Rankin JS,et al. Trends and outcomes of tricuspid valve surgery in North America:an analysis of more than 50,000 patients from the Society of Thoracic Surgeons database[J]. Ann Thorac Surg,2013,96(5):1546-1552; discussion 1552.
[4] Dahou A,Levin D,Reisman M,et al. Anatomy and Physiology of the tricuspid?valve[J]. JACC Cardiovasc Imaging,2019,12(3):458-468.
[5] Spinner EM,Shannon P,Buice D,et al. In vitro characterization of the mechanisms responsible for functional tricuspid regurgitation[J]. Circulation,2011,124(8):920-929.
[6] Singh JP,Evans JC,Levy D,et al. Prevalence and clinical determinants of mitral,tricuspid,and aortic regurgitation (the Framingham Heart Study)[J]. Am J Cardiol,1999,83(6):897-902.
[7] Yang L,Chen H,Pan W,et al. Analyses for prevalence and outcome of tricuspid regurgitation in China:an echocardiography study of 134,874 patients[J]. Cardiology,2019,142(1):40-46.
[8] Généreux P,Pibarot P,Redfors B,et al. Staging classification of aortic stenosis based on the extent of cardiac damage[J]. Eur Heart J,2017,38(45):3351-3358.
[9] Shiran A,Sagie A. Tricuspid regurgitation in mitral valve disease incidence,prognostic implications,mechanism,and management[J]. J Am Coll Cardiol,2009,53(5):401-408.
[10] Yoshida J,Ikenaga H,Hayashi A,et al. Predictors and outcomes of persistent tricuspid regurgitation after transcatheter aortic valve implantation[J]. Am J Cardiol,2019,124(5):772-780.
[11] Fender EA, Petrescu I, Ionescu F, et al. Prognostic Importance and Predictors of Survival in Isolated Tricuspid Regurgitation: A Growing Problem[J]. Mayo Clin Proc. 2019, 94(10): 2032-2039.
[12] Mutlak D,Khalil J,Lessick J,et al. Risk Factors for the Development of Functional Tricuspid Regurgitation and Their Population-Attributable Fractions[J]. JACC Cardiovasc Imaging,2020,13(8):1643-1651.
[13] Hahn RT. Tricuspid Regurgitation[J]. N Engl J Med,2023,388(20):1876-1891.
[14] Rodés-Cabau J,Taramasso M,O’Gara PT. Diagnosis and treatment of tricuspid valve disease:current and future perspectives[J]. Lancet,2016,388(10058):2431-2442.
[15] Rogers JH,Bolling SF. The tricuspid valve:current perspective and evolving management of tricuspid regurgitation[J]. Circulation,2009,119(20):2718-2725.
[16] Cohn LH. Tricuspid regurgitation secondary to mitral valve disease:when and how to repair[J]. J Card Surg,1994,9(suppl 2):237-241.
[17] Buzzatti N,de Bonis M,Moat N. Anatomy of the tricuspid valve,pathophysiology of functional tricuspid regurgitation,and implications for percutaneous therapies[J]. Interv Cardiol Clin,2018,7(1):1-11.
[18] Harjola VP,Mebazaa A,?elutkien? J,et al. Contemporary management of acute right ventricular failure:a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology[J]. Eur J Heart Fail,2016,18(3):226-241.
[19] Angeloni E,Melina G,Benedetto U,et al. Impact of prosthesis-patient mismatch on tricuspid valve regurgitation and pulmonary hypertension following mitral valve replacement[J]. Int J Cardiol,2013,168(4):4150-4154.
[20] 中国医师协会超声医师分会心脏超声专业委员会,中国医师协会心血管病分会结构性心脏病专业委员会,潘翠珍,等. 三尖瓣反流介入治疗的超声心动图评价中国专家共识(2021版) [J]. 中华超声影像学杂志,2021,30(6):461-471.
[21] Agarwal V,Hahn R. Tricuspid regurgitation and right heart failure:the role of imaging in defining pathophysiology,presentation,and novel management strategies[J]. Heart Fail Clin,2023,19(4):505-523.
[22] Addetia K,Miyoshi T,Citro R,et al. Two-dimensional echocardiographic right ventricular size and systolic function measurements stratified by sex,age,and ethnicity:results of the World Alliance of Societies of Echocardiography Study[J]. J Am Soc Echocardiogr,2021,34(11):1148-1157.e1141.
[23] Muraru D,Badano LP,Nagata Y,et al. Development and prognostic validation of partition values to grade right ventricular dysfunction severity using 3D echocardiography[J]. Eur Heart J Cardiovasc Imaging,2020,21(1):10-21.
[24] Lancellotti P,Pibarot P,Chambers J,et al. Multi-modality imaging assessment of native valvular regurgitation:an EACVI and ESC council of valvular heart disease position paper[J]. Eur Heart J Cardiovasc Imaging,2022,23(5):e171-e232.
[25] Naoum C,Blanke P,Cavalcante JL,et al. Cardiac computed tomography and magnetic resonance imaging in the evaluation of mitral and tricuspid valve disease:implications for transcatheter interventions[J]. Circ Cardiovasc Imaging,2017,10(3):e005331.
[26] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Thorac Cardiovasc Surg,2021,162(2):e183-e353.
[27] Ramsdell GC,Nelson JA,Pislaru SV,et al. Tricuspid regurgitation in congestive heart failure:management strategies and analysis of outcomes[J]. J Cardiothorac Vasc Anesth,2021,35(4):1205-1214.
[28] Henning RJ. Tricuspid valve regurgitation: current diagnosis and treatment[J]. Am J Cardiovasc Dis. 2022, 12(1): 1-18.
[29] Humbert M,Kovacs G,Hoeper MM,et al. 2 022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J,2023,61(1):2200879.
[30] Alqahtani F,Berzingi CO,Aljohani S,et al. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation[J]. J Am Heart Assoc,2017,6(12):e007597.
[31] Vassileva CM,Shabosky J,Boley T,et al. Tricuspid valve surgery:the past 10 years from the Nationwide Inpatient Sample (NIS) database[J]. J Thorac Cardiovasc Surg,2012,143(5):1043-1049.
[32] Feldman T,Foster E,Glower DD,et al. Percutaneous repair or surgery for mitral regurgitation[J]. N Engl J Med,2011,364(15):1395-1406.
[33] Braun D,Orban M,Orban M,et al. Transcatheter edge-to-edge repair for severe tricuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique[J]. JACC Cardiovasc Interv,2018,11(17):1790-1792.
[34] Mehr M,Taramasso M,Besler C,et al. 1-year outcomes after edge-to-edge valve repair for symptomatic tricuspid?regurgitation:results from the TriValve registry[J]. JACC Cardiovasc Interv,2019,12(15):1451-1461.
[35] Orban M,Rommel KP,Ho EC,et al. Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart?failure[J]. JACC Heart Fail,2020,8(4):265-276.
[36] Lurz P,Stephan von Bardeleben R,Weber M,et al. Transcatheter edge-to-edge repair?for?treatment of tricuspid?regurgitation[J]. J Am Coll Cardiol,2021,77(3):229-239.
[37] Zhang X,Jin Q,Pan W,et al. First-in-human study of the K-Clip? transcatheter annular repair system for severe functional tricuspid regurgitation[J]. Int J Cardiol,2023,390:131174.
[38] Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience[J]. JACC Cardiovasc Interv,2019,12(24):2488-2495.
[39] Baldus S,Schofer N,Hausleiter J,et al. Transcatheter valve repair of tricuspid regurgitation with the PASCAL system:TriCLASP study 30-day results[J]. Catheter Cardiovasc Interv,2022,100(7):1291-1299.
[40] Asmarats L,Perlman G,Praz F,et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation:insights from the first-in-human experience[J]. JACC Cardiovasc Interv,2019,12(15):1438-1447.
[41] Lu FL,Ma Y,An Z,et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients[J]. JACC Cardiovasc Interv,2020,13(13):1614-1616.
相似文献/References:
[1]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(7):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[2]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(7):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[3]张艺文 汪汉 秦莉 杨晓倩 童兰 蔡琳.狼疮患者冠心病的诊断、风险评估和治疗[J].心血管病学进展,2020,(5):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
ZHANG Yiwen,WANG Han,QIN Li,et al.Diagnosis, Risk Evaluation and Therapy of Coronary Heart Disease in Lupus Patients[J].Advances in Cardiovascular Diseases,2020,(7):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
[4]刘晓霞 吴宝全.外周血miR-26a-5p水平变化与高血压性左心室肥厚的关系分析[J].心血管病学进展,2020,(5):556.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.027]
LIU Xiaoxia,WU Baoquan.Relationship Between Changes of Peripheral Blood miR-26a-5p Levels and Hypertensive Left Ventricular Hypertrophy[J].Advances in Cardiovascular Diseases,2020,(7):556.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.027]
[5]袁佳栎 王群山.人工智能在心律失常诊断中的前景与挑战[J].心血管病学进展,2020,(10):999.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.001]
YUAN JialiWANG Qunshan.Prospects and Challenges of Arrhythmia Diagnosis by Artificial Intelligence[J].Advances in Cardiovascular Diseases,2020,(7):999.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.001]
[6]栾梦迪,吴立荣.院内发生的心肌梗死研究现况[J].心血管病学进展,2020,(10):1061.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.015]
LUAN Mengdi,WU Lirong.Research Status of AMI occurring in Hospitalized Patients[J].Advances in Cardiovascular Diseases,2020,(7):1061.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.015]
[7]王前程 刘伟涛 周忠江.提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识[J].心血管病学进展,2021,(3):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
WANG Qiancheng,LIU Weitao,ZHOU Zhongjiang.To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
[8]韩雅洁 范小倩 巩彩霞 赵子龙 乔成栋.致心律失常性左室心肌病的研究进展[J].心血管病学进展,2021,(4):342.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.013]
HAN Yajie,FAN Xiaoqian,GONG Caixia,et al.Arrhythmogenic Left Ventricular Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):342.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.013]
[9]余幸娟 王琦光.胎儿先天性心血管病诊疗现状与前景[J].心血管病学进展,2021,(6):547.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.017]
YU XingjuanWANG Qiguang.Current Situation and Prospect of Diagnosis and Treatment of Fetal Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2021,(7):547.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.017]
[10]张文倩 周玲梅 王超杰 张智伟.室间隔缺损合并主动脉瓣脱垂的诊断与治疗[J].心血管病学进展,2021,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.001]
ZHANG WenqianZHOU LingmeiWANG ChaojieZHANG Zhiwei.Diagnosis and Treatment of Ventricular Septal Defect with Aortic Valve Prolapse[J].Advances in Cardiovascular Diseases,2021,(7):673.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.001]